Abstract library

7 results for "90y-DOTATOC".
#989 AHCC Extract which Potentially Can Attenuate Immunological Toxicity in Patients with Neuroendocrine Tumors after Treatment with the Radioisotope Preparation (90Y-DOTA-TATE): An Initial Report
Introduction: Active hexose correlated compound (AHCC) is an alfa-glucan nutritional supplement made from the mycelia of Lentinula edodes mushroom. Human clinical studies have shown that AHCC significantly improves immune response, increases normal NK cell activity and enhances macrophage and T‑cell activity.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Norbert Szaluś
Keywords: AHCC, NET, PRRT
#1054 Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Hepatic arterial embolization with 90Y-labelled microspheres is a method of delivering radioactivity to liver tumors, that has been used to treat primary hepatocellular carcinomas and liver metastases from colorectal carcinomas and neuroendocrine tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Associate Prof Dan Granberg
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms
Introduction: A
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD, PhD Miroslaw L Nowicki
#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment
#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan
Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Sean X Yan
Authors: Yan S X, Lim G K, ...
#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Arthur Braat